Last reviewed · How we verify

Actamer — Competitive Intelligence Brief

Actamer (BITHIONOL) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: bithionol. Area: Rare Disease.

marketed bithionol N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D, Adenosine receptor A3, Mitogen-activated protein kinase 1 Rare Disease Small molecule Live · refreshed every 30 min

Target snapshot

Actamer (BITHIONOL).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Actamer TARGET BITHIONOL marketed bithionol N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D, Adenosine receptor A3, Mitogen-activated protein kinase 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (bithionol class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Actamer — Competitive Intelligence Brief. https://druglandscape.com/ci/bithionol. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: